News | FDA

Top News

Woodcock Becomes Acting FDA Commissioner Following Hahn’s Resignation as Biden Administration Begins

Full Article

January 22, 2021
OPDP Issues Second Untitled Letter of 2020

Full Article

December 4, 2020
PhRMA, Other Groups Sue HHS, FDA To Block Rule Allowing Importation of Rx Drugs from Canada

Full Article

December 3, 2020
GAO Finds Persistent COVID-19 Supply Shortages, Inconsistent Testing Guidance from Federal Agencies

Full Article

December 2, 2020
HHS Shuts Down FDA’s Unapproved Drugs Initiative, Saying It Led to Price Increases, Product Shortages

Full Article

November 24, 2020

LATEST HEADLINES

Woodcock Becomes Acting FDA Commissioner Following Hahn’s Resignation as Biden Administration Begins

January 22, 2021
Fruit Juice Maker Shut Down Under Terms of Consent Decree After Years of cGMP, HACCP Violations

January 21, 2021
Journal Article Scrutinizes Nurse Ambassador Programs

January 21, 2021
FTC, FDA Move Against Dozens of Supplement Firms Making False COVID-19 Claims

January 21, 2021
FDA Announces Plan for Regulating Software Devices Using Artificial Intelligence, Machine Learning

January 20, 2021
FCC: Recorded Phone Trial Recruitment Pitches Are OK

January 19, 2021
HHS Permanently Exempts Seven COVID-19-Related Medical Devices from FDA’s 510(k) Requirements

January 14, 2021
Court Shuts Down Supplement Company That Claimed Its Vitamin D Products Could Treat COVID-19

January 14, 2021
Investigator Pleads Guilty to Conspiring To Falsify Trial Data

January 12, 2021
N.Y. Assembly Bill Aims To Keep Individual Prescribing Data Confidential

January 11, 2021

Latest FDA Intelligence

Latest FDA Intended Use Proposal Lacks Clarity, Falls Short on Legal Grounds, Comments Assert

January 15, 2021
Untitled Letter Provides Reminder of Basic Promotion Requirements

December 30, 2020
OPDP Issues Few Enforcement Letters in 2020 But They Have High Impact

December 30, 2020
Speaker Program Reexamination Needed After OIG Alert

December 7, 2020
Administration’s Most Favored Nation Pricing Plan Could Affect Industry Profitability

November 23, 2020

NEWSLETTERS

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1611675772
            [c] => 1611675772
            [l] => 2000000
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1611675772
            [c] => 1611675772
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1611675772
            [c] => 1611675772
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1611675772
            [c] => 1611675772
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Array
(
    [_sf2_attributes] => Array
        (
        )

    [_symfony_flashes] => Array
        (
        )

    [_sf2_meta] => Array
        (
            [u] => 1611675772
            [c] => 1611675772
            [l] => 2000000
        )

    [fda] => Array
        (
            [last_user_access] => 
        )

)

Top News

Woodcock Becomes Acting FDA Commissioner Following Hahn’s Resignation as Biden Administration Begins

OPDP Issues Second Untitled Letter of 2020

PhRMA, Other Groups Sue HHS, FDA To Block Rule Allowing Importation of Rx Drugs from Canada

GAO Finds Persistent COVID-19 Supply Shortages, Inconsistent Testing Guidance from Federal Agencies

HHS Shuts Down FDA’s Unapproved Drugs Initiative, Saying It Led to Price Increases, Product Shortages

LATEST HEADLINES

Latest FDA Intelligence

Latest FDA Intended Use Proposal Lacks Clarity, Falls Short on Legal Grounds, Comments Assert

Untitled Letter Provides Reminder of Basic Promotion Requirements

OPDP Issues Few Enforcement Letters in 2020 But They Have High Impact

Speaker Program Reexamination Needed After OIG Alert

Administration’s Most Favored Nation Pricing Plan Could Affect Industry Profitability

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT